Related Experiment Video

Updated: Jun 21, 2026

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Therapeutic options for triple-negative breast cancers with defective homologous recombination

Janneke E Jaspers1, Sven Rottenberg, Jos Jonkers

  • 1Division of Molecular Biology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Biochimica Et Biophysica Acta
|July 21, 2009
PubMed

Insights

Triple-negative breast cancer lacks targeted therapies. Research suggests BRCA1-mutated tumors share features with triple-negative cancers, offering potential new treatment strategies and insights from mouse models.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Breast cancer is a leading cause of cancer death in women globally.
  • Effective targeted therapies exist for hormone receptor-positive and HER2-expressing breast cancers.
  • Triple-negative breast cancer (TNBC) currently lacks specific targeted treatment options.

Purpose of the Study:

  • To review shared features among triple-negative, basal-like, and BRCA1-related breast cancers.
  • To discuss novel therapeutic strategies for BRCA1-mutated and BRCA1-like TNBC.
  • To highlight the role of mouse models in advancing TNBC therapy.

Main Methods:

  • Literature review of breast cancer biology and genetics.
  • Analysis of overlapping characteristics between different breast cancer subtypes.
  • Discussion of preclinical models for therapeutic development.

Main Results:

  • Significant overlap exists between BRCA1-mutated breast cancers and triple-negative tumors.
  • BRCA1-deficient cells present a potential therapeutic target for a subset of TNBC.
  • Mouse models are crucial for optimizing combination therapies and understanding resistance mechanisms.

Conclusions:

  • Targeting BRCA1 deficiency offers a promising avenue for treating specific triple-negative breast cancers.
  • Further research into BRCA1-mutated and BRCA1-like breast cancers is essential for developing new treatments.
  • Preclinical models are vital for translating research findings into effective clinical strategies for breast cancer.

More Related Videos

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Homologous Recombination02:31

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
Homologous Recombination02:31

Homologous Recombination

The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
Fixing Double-strand Breaks02:04

Fixing Double-strand Breaks

The double-stranded structure of DNA has two major advantages. First, it serves as a safe repository of genetic information where one strand serves as the back-up in case the other strand is damaged. Second, the double-helical structure can be wrapped around proteins called histones to form nucleosomes, which can then be tightly wound to form chromosomes. This way, DNA chains up to 2 inches long can be contained within microscopic structures in a cell. A double-stranded break not only damages...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...